---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000156"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:15:57.536402+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Summit reports Q3 net loss $56.3M; ivonescimab HARMONi-2 shows 49% risk reduction vs Keytruda

## Summary
- Cash and short-term investments $487M (vs $186.2M Dec 2023) after $235M private financing in Sep 2024.
- GAAP net loss $56.3M ($0.08/share) vs $21.2M ($0.03/share) in Q3 2023; R&D spend $37.7M.
- Ivonescimab in HARMONi-2 (NSCLC) reduced disease progression/death by 49% vs pembrolizumab (HR 0.51; p<0.0001).
- HARMONi (2L+ EGFRm) enrollment complete; topline mid-2025. HARMONi-3 to expand to non-squamous; HARMONi-7 to start early 2025.
- Phase II data at ESMO/WCLC showed 71.8% MPR in perioperative NSCLC, 84.6% ORR in MSS CRC, 72.4% ORR in TNBC.

## SEC filing metadata
- accession: 0001599298-24-000156
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000156/0001599298-24-000156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000156/smmt-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000156
- JSON: https://secwatch.observer/filing/0001599298-24-000156.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.